Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom

BACKGROUND: Patients with highly active relapsing-remitting multiple sclerosis inadequately responding to first-line therapies (interferon-based therapies, glatiramer acetate, dimethyl fumarate, and teriflunomide, known collectively as “BRACETD”) often switch to natalizumab or fingolimod. OBJECTIVE:...

Descripción completa

Detalles Bibliográficos
Autores principales: Spelman, Timothy, Herring, William L., Zhang, Yuanhui, Tempest, Michael, Pearson, Isobel, Freudensprung, Ulrich, Acosta, Carlos, Dort, Thibaut, Hyde, Robert, Havrdova, Eva, Horakova, Dana, Trojano, Maria, De Luca, Giovanna, Lugaresi, Alessandra, Izquierdo, Guillermo, Grammond, Pierre, Duquette, Pierre, Alroughani, Raed, Pucci, Eugenio, Granella, Franco, Lechner-Scott, Jeannette, Sola, Patrizia, Ferraro, Diana, Grand’Maison, Francois, Terzi, Murat, Rozsa, Csilla, Boz, Cavit, Hupperts, Raymond, Van Pesch, Vincent, Oreja-Guevara, Celia, van der Walt, Anneke, Jokubaitis, Vilija G., Kalincik, Tomas, Butzkueven, Helmut
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8866337/
https://www.ncbi.nlm.nih.gov/pubmed/34921350
http://dx.doi.org/10.1007/s40273-021-01106-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8866337/
https://www.ncbi.nlm.nih.gov/pubmed/34921350
http://dx.doi.org/10.1007/s40273-021-01106-6

Ejemplares similares